CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

 

Anti-HER2/neu Therapy:

Is Adjuvant Trastuzumab for All HER2-Positive Breast Cancer Regardless of Tumor Characteristics?


Supported by an educational grant from
Genentech BioOncology
2 AMA PRA Category 1 Credit(s)™

IMPORTANT INFORMATION

To assure continuity of documentation, AMA PRA Category 1 Credits™ originally designated by Beam Institute will now be provided by CME LLC.

CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


AUTHORS: Chau T. Dang, MD
Clinical Assistant Physician
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Clifford Hudis, MD
Chief
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York

EDITOR: Matthew J. Ellis, MB, BChir, PhD, FRCP
Director, Breast Cancer Program
Anheuser Busch Tenured
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri | May 1, 2008

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Head and Neck Tumors
  • 46-Year-Old Woman Presents With Difficulty in Ambulation, and Swelling and Discoloration of Both Eyelids
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • New Mutation May Act as Driver in Subset of Lung Cancer Patients
  • Could Aspirin Be a Viable Adjuvant Treatment for Cancer?
  • Advances and New Research in the Treatment of Kidney Cancer
  • New Way to Predict Prostate Cancer Severity—Size of Prostate
  • Vismodegib Granted FDA Approval for Treatment of Basal Cell Carcinoma
  • FDA Grants Approval to Axitinib for the Treatment of Advanced Renal Cell Carcinoma
  • Why BRAF-Mutated Colorectal Cancers Don't Respond to BRAF Inhibitors
Click here to subscribe to our newsletter
 
CME ACTIVITIES

Optimal Care for HER2+ Breast Cancer

An interactive case challenge activity.

 

The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.

 

 Go to Activity
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Sign up for our
Newsletters
Subscribe to our
RSS Feed
CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy